These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Passive enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season. Dos Santos G; Yeakey A; Shende V; Smith K; Lin F; Zandman-van-Dijk E; Damaso S; Schmidt A BMJ Open; 2019 Aug; 9(8):e028043. PubMed ID: 31427321 [TBL] [Abstract][Full Text] [Related]
7. Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season. Dos Santos G; Nguyen BY; Damaso S; Godderis L; Martínez-Gómez X; Eckermann T; Loos H; Salamanca de la Cueva I; Shende V; Schmidt AC; Yeakey A Drug Saf; 2020 Mar; 43(3):265-279. PubMed ID: 31884676 [TBL] [Abstract][Full Text] [Related]
8. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Bricout H; Chabanon AL; Souverain A; Sadorge C; Vesikari T; Caroe TD Euro Surveill; 2017 May; 22(18):. PubMed ID: 28494843 [TBL] [Abstract][Full Text] [Related]
9. Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis. Dos Santos G; Shende V; Damaso S; Yeakey A Adv Ther; 2019 Dec; 36(12):3340-3355. PubMed ID: 31595482 [TBL] [Abstract][Full Text] [Related]
10. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season. Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589 [TBL] [Abstract][Full Text] [Related]
11. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study. Stuurman AL; Verstraeten T; De Schryver A Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801 [TBL] [Abstract][Full Text] [Related]
12. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season. Chabanon AL; Wague S; Moureau A; Nissila M; Serradell L BMC Public Health; 2021 Feb; 21(1):358. PubMed ID: 33588815 [TBL] [Abstract][Full Text] [Related]
13. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older. Dos Santos G; Devadiga R; Kim CS; Bang J Drug Saf; 2024 Apr; 47(4):365-375. PubMed ID: 38483767 [TBL] [Abstract][Full Text] [Related]
14. Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England. McNaughton R; Lynn E; Osborne V; Coughtrie A; Layton D; Shakir S Drug Saf; 2016 Apr; 39(4):323-33. PubMed ID: 26798051 [TBL] [Abstract][Full Text] [Related]
15. Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21. Syrkina O; Inamdar A; Wague S; Monfredo C; Nissilä M; Chabanon AL; Serradell L BMC Public Health; 2022 Aug; 22(1):1506. PubMed ID: 35941631 [TBL] [Abstract][Full Text] [Related]
16. Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. Simpson CR; Lone NI; Kavanagh K; Robertson C; McMenamin J; von Wissmann B; Vasileiou E; Butler C; Ritchie LD; Gunson R; Schwarze J; Sheikh A BMJ Open; 2017 Feb; 7(2):e014200. PubMed ID: 28246142 [TBL] [Abstract][Full Text] [Related]
17. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. Pillsbury AJ; Glover C; Jacoby P; Quinn HE; Fathima P; Cashman P; Leeb A; Blyth CC; Gold MS; Snelling T; Macartney KK BMJ Open; 2018 Oct; 8(10):e023263. PubMed ID: 30341132 [TBL] [Abstract][Full Text] [Related]
18. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026 [TBL] [Abstract][Full Text] [Related]
19. Rapid assessment of enhanced safety surveillance for influenza vaccine. Alguacil-Ramos AM; Portero-Alonso A; Pastor-Villalba E; Muelas-Tirado J; Díez-Domingo J; Sanchis-Ferrer A; Lluch-Rodrigo JA Public Health; 2019 Mar; 168():137-141. PubMed ID: 30769245 [TBL] [Abstract][Full Text] [Related]